The Innovative Cancer Treatments of Tomorrow are Born Through Collaboration

​Annette Hay, Senior Investigator and Co-PI of ExCELLirate Canada, the CCTG-co-Led national platform for exploring the promising applications of cell therapy research across a wide variety of cancers and other illnesses was recently featured as a signature initiative at Queen’s University.

More >>

Publication: BR34

The CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer study results were recently published in the Journal of Thoracic Oncology.

More >>
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).

More >>

Planned trials


MRD Driven Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML


Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials


Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)


Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)


MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

More >>


Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC


Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)


Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma


SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

More >>


PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)


Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)


De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)


NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET


Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy


A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

Recently activated


Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

More >>


Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

More >>


COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

More >>


Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

More >>


Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

More >>
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>


Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

J Am Med Assoc 327: 1963 - 1973, 2022
Goodwin PJ;Chen BE;Gelmon KA;Whelan TJ;Ennis M;Lemieux J;Ligibel JA;Hershman DL;Mayer IA;Hobday TJ;Bliss JM;Rastogi P;Rabaglio-Poretti M;Mukherjee SD;Mackey JR;Abramson VG;Oja C;Wesolowski R;Thompson AM;Rea DW;Stos PM;Shepherd LE;Stambolic V;Parulekar WR;

More >>

Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study (ONLINE)

Eur J Can 170: 1 - 9, 2022
Machingura A;Taye M;Musoro J;Ringash J;Pe M;Coens C;Martinelli F;Tu D;Basch E;Brandberg Y;Gr?nvold M;Eggermont A;Cardoso F;Van Meerbeeck J;van der Graaf WTA;Taphoorn M;Reijneveld JC;Soffietti R;Sloan J;Velikova G;Flechtner H;Bottomley A;

More >>

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial (ONLINE)

J Clin Oncol , 2022
Liu JF;Brady MF;Matulonis UA;Miller A;Kohn EC;Swisher EM;Cella D;Tew WP;Cloven NG;Muller CY;Bender DP;Moore RG;Michelin DP;Waggoner SE;Geller MA;Fujiwara K;D'Andre SD;Carney M;varez Secord A;Moxley KM;Bookman MA;

More >>

Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery : OF1 - OF10, 2022
Grossmann KF;Othus M;Patel SP;Tarhini AA;Sondak VK;Knopp MV;Petrella TM;Truong TG;Khushalani NI;Cohen JV;Buchbinder EI;Kendra K;Funchain P;Lewis KD;Conry RM;Chmielowski B;Kudchadkar RR;Johnson DB;Li H;Moon J;Eroglu Z;Gastman B;Kovacsovics-Bankowski M;Gunturu KS;Ebbinghaus SW;Ahsan S;Ibrahim N;Sharon E;Korde LA;Kirkwood JM;Ribas A;

More >>

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebocontrolled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

, 2022
McBride SM;Niazi T;Williams S;Davis ID;Stockler M;Martin AJ;Bracken K;Roncolato FT;Horvath L;Sengupta S;Martin J;Lim T;Hughes S;McDermott RS;Catto JWF;Kelly PJ;Parulekar WR;Morgan SC;Rendon RA;Sweeney C;

More >>

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

J Immunother Cancer 10: e004310, 2022
Tarhini AA;Lee SJ;Tan AC;El Naqa IM;Stephen Hodi F;Butterfield LH;LaFramboise WA;Storkus WJ;Karunamurthy AD;Conejo-Garcia JR;Hwu P;Streicher H;Sondak VK;Kirkwood JM;

More >>